Identification of a prognostic biomarker predicting biochemical recurrence and construction of a novel nomogram for prostate cancer

Abstract

BackgroundBiochemical recurrence (BCR) is common in prostate cancer (PCa), but its prediction is based predominantly on clinicopathological characteristics with low accuracy. We intend to identify a potential prognostic biomarker related to the BCR and construct a nomogram for improving the risk stratification of PCa patients.MethodsThe transcriptome and clinical data of PCa patients were obtained from TCGA and GEO databases. Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were used to screen out differentially expressed genes (DEGs) related to the BCR of PCa. Cox regression analysis was further applied to screen out DEGs related to BCR-free survival (BFS). Time-dependent receiver operating curve (ROC) analysis and Kaplan–Meier (K-M) survival analysis were conducted to assess the prognostic value. Then, a prognostic nomogram was established and evaluated. The clinicopathological correlation analysis, GSEA analysis, and immune analysis were used to explore the biological and clinical significance of the biomarker. Finally, the qRT-PCR, western blotting, and immunohistochemistry (IHC) were conducted to validate the expression of the biomarker.ResultsBIRC5 was identified to be the potential prognostic biomarker. The clinical correlation analysis and K-M survival analysis found that the BIRC5 mRNA expression was positively associated with disease progression and negatively associated with the BFS rate. Time-dependent ROC curves verified its accurate prediction performance. The GSEA and immune analysis suggested that the BIRC5 was related to immunity. A nomogram with an accurate prediction for BFS of PCa patients was constructed. qRT-PCR, western blotting, and IHC results validated the expression level of BIRC5 in PCa cells and tissues.ConclusionOur study identified BIRC5 as a potential prognostic biomarker related to BCR of PCa and constructed an efficacy nomogram for predicting BFS to assist clinical decision-making.

Deciphering hepatocellular carcinoma pathogenesis and therapeutics: a study on anoikis, ceRNA regulatory network and traditional Chinese medicine

“…Among the selected genes, BIRC5 is an immune-related gene that inhibits apoptosis and promotes cell proliferation. There is increasing evidence suggesting the crucial role of BIRC5 in tumorigenesis, as it is overexpressed in various cancers such as breast cancer (Cao et al, 2023), oral squamous cell carcinoma (Cacına et al, 2023), benign meningioma (Maier et al, 2023), prostate cancer (Yu et al, 2023) and ovarian cancer (Li B. et al, 2023), thereby indicating a poor prognosis in cancer patients. Additionally, E2F1 is a wellknown transcription factor that regulates the cell cycle and cell proliferation by binding to specific sites in the promoters of its downstream target genes to upregulate their expression.…”

Crucial role of hsa-mir-503, hsa-mir-1247, and their validation in prostate cancer

“…In the worldwide, the incidence rate of standardized age of PC increased from 30.5 cases per 100 thousand population in 1990 to 37.9 cases per 100 thousand population in 2017, showing a gradual increasing trend [ 2 ]. The great development and popularity of prostate-specific antigen (PSA) screening and prostate needle biopsy technology makes it possible for more patients with PC to be diagnosed at an early-stage [ 3 ]. Although most of these patients could benefit from the radical prostatectomy, unfortunately, approximately 20–40% localized PC patients would eventually suffer from a biochemical recurrence [ 4 ].…”